Altamira Therapeutics .(CYTO) - 2020 Q4 - Annual Report

Exhibit 99.1 Auris Medical Provides Business Update and Reports Second Half and Full Year 2020 Financial Results ● Clinical evaluation of AM-301 nasal spray in allergen protection progressing ● Launch of AM-301 expected in selected markets towards the end of second quarter 2021 ● Phase 2 trial with AM-125 in acute vertigo expected to complete enrollment in third quarter 2021 ● Equity and cash position significantly strengthened ● Strategy review ongoing Hamilton, Bermuda, March 31, 2021 – Auris Medical Hold ...